Metraipolis › archive › dc_ce30de73553b
BMB-105 — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/BMB-105
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-10T17:26:38.683Z
- SHA-256 of the archived text
8e5f8bae3add1a7543c019b9f1d22ef1821ae5a8b2ae3df2382433b62260f1ca- Stable URL of this page
https://metraipolis.com/documento/dc_ce30de73553b
How to cite
BMB-105 — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/BMB-105 (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_ce30de73553b (Metraipolis archive dc_ce30de73553b, sha256 8e5f8bae3add1a7543c019b9f1d22ef1821ae5a8b2ae3df2382433b62260f1ca)
BibTeX
@misc{dcce30de73553b,
title = {BMB-105 — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/BMB-105},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_ce30de73553b; sha256 8e5f8bae3add1a7543c019b9f1d22ef1821ae5a8b2ae3df2382433b62260f1ca},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/BMB-105. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
BMB-105 is a selective serotonin 5-HT2C receptor agonist of the phenylcyclopropylmethylamine (PCPMA) family which is under development for the treatment of excessive appetite and other symptoms in Prader–Willi syndrome. It is taken orally. The drug is described as a highly selective biased agonist of the serotonin 5-HT2C receptor, with activation of the Gq signaling pathway but minimal β-arrestin recruitment. BMB-105 is under development by Bright Minds Biosciences. As of November 2025, it is in phase 1 clinical trials. The drug is described as a follow-on drug to Bright Mind Bioscience's more advanced candidate BMB-101 and as a potential "best-in-class" medication. The exact chemical structure of BMB-105 does not yet appear to have been disclosed. However, it is known to be a 2-phenylcyclopropylmethylamine (PCPMA) derivative similarly to BMB-101 and to share structural commonalities with tranylcypromine. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «BMB-105» — https://en.wikipedia.org/wiki/BMB-105 Wikidata Q139257547: «pharmaceutical compound» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q139257547 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/BMB-105?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1365339404, consultata il 2026-11-10T17:23:32.496Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: f9a1dc41cd415ff9acfdb3cf8aae0129ae9e29c0741be72af6ef0348c496e635